fulvestrant

Type: Keyphrase
Name: fulvestrant
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Breast cancer patients miss out on management plans

Chronic disease management plans should be routinely offered to secondary breast cancer patients, according to a national report that found four in five patients are missing out on the medical and financial benefits of subsidised care.Only 21% of women ... [Published Australian Doctor - 9 hours ago]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Court Report - September 2014 #6

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Cadence Pharmaceuticals Inc. et al. v. InnoPharma Licensing LLC et al.1:14-cv-01225; filed September 24, 2014 in the District Court of Delaware• Plaintiffs:  ... [Published JD Supra - Sep 29 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

CLOVIS ONCOLOGY : Reports on Lucitanib Phase 2 Study

Clovis Oncology reported that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site."Early lucitanib data are encouraging, and suggest that determination of ... [Published 4 Traders - Sep 24 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Chronic

Recently I was dining with friends, enjoying a pleasant Palo Alto evening on their porch. We noticed a family of quail walking on the ledge of the wooden fence that enclosed the yard, a mother and her brood of children. They hopped down into the yard. ... [Published Oncology Times - Sep 19 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Array BioPharma, Inc. (ARRY) Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published FierceBiotech - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Researchers examine role of hormone in response to ovarian cancer treatment

PUBLIC RELEASE DATE: 17-Sep-2014The work comes out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, of Women & Infants' Program in Women's Oncology. Entitled "HE4 expression is associated with hormonal elements and mediated by ... [Published EurekAlert! - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Court Report - September 2014 #4

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Millennium Pharmaceuticals Inc. v. Glenmark Pharmaceuticals Ltd. et al.1:14-cv-01156; filed September 10, 2014 in the District Court of Delaware• Plaintiff:  ... [Published JD Supra - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Array BioPharma : Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published 4 Traders - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

CDK 4/6, PI3K Inhibitor Combinations Explored in Breast Cancer

Pamela N. Munster, MDThe combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer, according phase Ib data presentation by ... [Published OncLive - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Groundbreaking drug trial offers new hope to Welsh breast cancer patients

A radiographer has become the first person in the world to trial a new drug combination which doctors hope could help women with breast cancer.Susanne Jones, from Barry in the was diagnosed with breast cancer in 2006.A year-and-a-half after treatment, ... [Published Wales Online - Sep 10 2014]
First reported Sep 07 2014 - Updated Sep 07 2014 - 1 reports

Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer

Mahmoud Charif, MDThe addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with estrongen receptor (ER)-positive metastatic breast cancer, according a presentation by Mahmoud Charif, MD, at the ... [Published OncLive - Sep 07 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Pfizer : Announces Submission of Palbociclib New Drug Application to the FDA

By a News Reporter-Staff News Editor at Biotech Week -- Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, ... [Published 4 Traders - Aug 28 2014]

Quotes

"Women with breast cancer should be encouraged to discuss management plan options with their GP" the report concluded, adding that breast cancer specialists should communicate with GPs about putting management plans in place
Infringement of U S Patent Nos. 8,017,615 ( "Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof" issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), and 8,642,760 (same title, issued February 4, 2014) following a Paragraph...
"Early lucitanib data are encouraging, and suggest that determination of genetic alterations in the FGF pathway may be important to identify the patients most likely to benefit from lucitanib treatment" said Carlos Arteaga , Associate Director for Clinical ResearchResearch DirectorDirector of the Center for Cancer Targeted Therapies , and Director of...
...efforts as we advance our late-stage, wholly-owned assets toward commercialization," said Ron Squarer, Chief Executive Officer, Array BioPharma.  "With the possible near-term return of binimetinib to Array, his expertise will have significant impact on our long-term success."

More Content

All (18) | News (17) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Breast cancer patients miss out on management p... [Published Australian Doctor - 9 hours ago]
Court Report - September 2014 #6 [Published JD Supra - Sep 29 2014]
CLOVIS ONCOLOGY : Reports on Lucitanib Phase 2 ... [Published 4 Traders - Sep 24 2014]
Chronic [Published Oncology Times - Sep 19 2014]
Array BioPharma, Inc. (ARRY) Appoints Victor Sa... [Published FierceBiotech - Sep 19 2014]
Researchers examine role of hormone in response... [Published EurekAlert! - Sep 17 2014]
Court Report - September 2014 #4 [Published JD Supra - Sep 15 2014]
Array BioPharma : Appoints Victor Sandor, M.D.,... [Published 4 Traders - Sep 11 2014]
CDK 4/6, PI3K Inhibitor Combinations Explored i... [Published OncLive - Sep 11 2014]
Groundbreaking drug trial offers new hope to We... [Published Wales Online - Sep 10 2014]
Adding Trastuzumab to Fulvestrant Prolongs Resp... [Published OncLive - Sep 07 2014]
Pfizer : Announces Submission of Palbociclib Ne... [Published 4 Traders - Aug 28 2014]
Mount Kisco Medical Group and Northern Westches... [Published PRWeb - Jun 24 2014]
Pfizer to submit palbociclib NDA with US FDA ba... [Published PharmaBiz - May 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Fulvestrant 500 mg vs 250 mg in CONFIRM Trial [Published BioPortfolio - Feb 13 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.